Chemometrics and Monte-Carlo Simulation Assisted RP-LC Method for Estimation of Cinacalcet Hydro- chloride in Pharmaceutical Products
DOI:
https://doi.org/10.37285/ijpsn.2021.14.2.9Abstract
Cinacalcet hydrochloride (CNT) is a novel calcimimetic agent widely used in the treatment of hyperparathy- roidism. For the first time, the authors utilized the novel concept of analytical procedure development employing several unique scientific tools for quantification CNT from its pharmaceutical dosage form. The objective behind the present work was to establish a scientifically sound and systematic work frame that overcomes the drawbacks of the earlier reported method for estimating CNT level in samples and ensuring superior method performance throughout the analytical life-cycle. In this process, at first, the risky method variables were earmarked and were subjected to a response surface methodology, followed by Monte-Carlo simulation (MCS) based robust- ness-cum-optimization studies. The inclusion of the MCS approach assessed the method performance with no additional laboratory experimentation and established the innovative hyphenation's aptness with chemometrics tools. The control strategies were established based on analytical design space and method performance evaluation results by a simulative approach. The study revealed that methanol %, flow rate, and pH are the three critical method variables influencing analytical attributes: retention time, the number of plates, and tailing. The analytical conditions include a C18 column (150mm × 4.6mm, 5μm) with an isocratic mobile phase (80:20, % v/v) of methanol and 0.01M KH2PO4 buffer (pH maintained at 3.5 using orthophosphoric acid) flowing at 1.1ml/min. Diode array detection was performed at 282 nm. Method validation was befitting to federal needs as linearity (0.5-160 μg/ml), accuracy (>99%), and precision below 1% of relative standard deviation are indicative of method suitability for the purpose. In a nutshell, the present method describes a typical analytical workflow with the significant advantage of obtaining more excellent scientific information with less systematized experimentation. It was found suitable for routine quality control of CNT in drug substance and drug product.
Downloads
Metrics
Keywords:
Cinacalcet, Design of experiments, Design space, Liquid chromatography, Monte-Carlo simulation, Risk assessment
Downloads
Published
How to Cite
Issue
Section
References
Agrahari V, Meng J, Zhang T, and Youan BC (2014). Application of design of experiment and simulation methods to liquid chromatography analyss of topical HIV microbicides stampidine and HI443. J Anal Bioanal Tech 5: 180. DOI: 10.4172/2155- 9872.1000180.
Balfour JAB, and Scott LJ (2005). Cinacalcet hydrochloride. Drugs 54: 271-81.
Bandaru S, Sirisilla R, Reddy PA, Reddy AN, Reddy RP, Reddy RB, Thaduri NR, and Singavarapu T (2015). Development of validated stability-indicating HPLC method for the determination of cinacalcet hydrochloride and its impurities. Int J Modern Chem Appl Sci2:57-64.
Beg S, Panda SS, Katare OP, and Singh B (2017). Applications of Monte-Carlo simulation and chemometric techniques for development of bioanalytical liquid chromatography method for estimation of rosuvastatin calcium. J LiqChromatogrRelat Technol 40: 907-920.DOI: 10.1080/10826076.2017.1382377.
Bezerra MA, Santelli RE, Oliveira EP, Villar LS and Escaleria LA (2008) Response surface methodology as a tool for optimization in analytical chemistry. Talanta 76: 965-977. DOI: 10.1016/j.talanta.2008.05.019.
Cangemi G, Barco S, Verrina EE, Scurati S, Melioli G, and Alberighi ODC (2013).Micromethod for quantification of cinacalcet in human plasma by liquid chromatography-tandem mass spectrometry using a stable isotope-labeled internal standard. Ther Drug Monit 35: 112-117. DOI:10.1097/FTD.0b013e318278dc69.
Cielecka-Piontek J, Zalewski P, Jelinska A, and Garbacki P (2013) UHPLC: the greening face of liquid chromatography. Chromatographia 76: 1429-1437. DOI: 10.1007/s10337-013-2434-
Dejaegher B and Heyden YV (2011) Experimental designs and their recent advances in set-up, data interpretation, and analytical applications. J Pharm Biomed Anal 56: 141-158. DOI: 10.1016/ j.jpba.2011.04.023.
Dong BJ (2005). Cinacalcet: an oral calcinomimetic agent for the management of hyperparathyroidism. Clin Ther 27:1725-1751. DOI: 10.1016/j.clinthera.2005.11.015.
Frnoudian-Habibi A, and Jaymand M (2016). Separation and quantitative determination of cinacalcet metabolites in urine sample using RP-HPLC after derivation with a fluorescent labeling reagent.J Chromatogr B 1027: 214-220. DOI:10.1016/ j.jchromb.2016.05.047.
Frnoudian-Habibi A, and Jaymand M (2017). Development and validation of a quantitative assay for the determination of cinacalcet and its main metabolites in human plasma using RP- HPLC method. Microchem J 130: 377-383. DOI: 10.1016/j.microc.2016.10.017.
Gumustas M, Kurbanoglu S, Uslu B, and Ozkan SA (2013) UPLC versus HPLC on drug analysis: advantageous, applications and their validation parameters. Chromatographia 76: 1365-1427. DOI:10.1007/s10337-013-2524-5.
International Conference on Harmonization of Technical Requirements for Registrationof Pharmaceuticals for Human Use (2018). Analytical Procedure Development and Revision of Q2(R1) Analytical Validation Q14, Harmonized Tripartite Guideline: Final Concept Paper, Geneva, Switzerland
International Conference on Harmonization of Technical Requirements for Registrationof Pharmaceuticals forHuman Use (2005). Validation of Analytical Procedures: Text and Methodology Q2(R1), Harmonized Tripartite Guideline, Geneva, Switzerland.
International Conference on Harmonization of Technical Requirements for Registrationof Pharmaceuticals for Human Use (2005). Quality Risk Management Q9, Harmonized Tripartite Guideline, Geneva, Switzerland.
Jackson P, Borman P, Campa C, Chatfield M, Godfrey M, Hamilton P, Hoyer W, Norelli F, and Orr R (2019). Using the analytical target profile to drive the analytical method lifecycle. Anal Chem 91: 2577-2585. DOI: 10.1021/acs.analchem.8b04596.
Nirogi R, Kandikere V, Komarneni P, Aleti R, Padala NSP, and Kalaikadiban I (2011). Quantification of cinacalcet by LC- MS/MS using liquid-liquid extraction from 50μl of plasma. J Pharm Biomed Anal 56: 373-381.DOI: 10.1016/j.jpba.2011. 05.032.
Novakova L, Matysova L, and Solich P (2006). Advantages of application of UPLC in pharmaceutical analysis. Talanta 68: 908-918. DOI: 10.1016/j.talanta.2005.06.035.
Panda SS, Bera VVRK, Beg S, and Sahu SK (2015). Ultrafast liquid chromatographic method development and its validation for quantification in pharmaceutical dosage form by using quality by design approach. J Chromatogr Sci 53: 1193-1202. DOI: 10.1093/chromsci/bmu228.
Panda SS, Bera VVRK, Acharjya SK, Sahoo P, and Beg S (2019). Analytical lifecycle management approach: application to development of a reliable LC method for estimation of lacidipine. Sep Sci Plus 2: 18-25. DOI: 10.1002/sscp.201800110.
Panda SS, Bera VVRK, and Panda J (2020).Chemomtery assisted diffuse reflectance infrared fourier transform spectroscopy (DRIFTS) method for quantification of a novel antipsychotic agent in pharmaceuticals: a case study on ICH Q 14 concept. VibSpectrosc 107: 103039. DOI: 10.1016/j.vibspec.2020.103039.
Panigrahi D, Mishra A and Sahu SK (2018). Development and validation of a RP-HPLC method for quantitative estimation of cinacalcet in tablet dosage form. World J Pharm Res 7: 1016- 1025.DOI: 10.20959/wjpr201819-13749.
Poole CF and Lenca N Reversed Phase Liquid Chromatography; Fanali S, Haddad PR, Poole CF and Riekolla ML. In: Liquid Chromatography: Fundamentals and Instrumentation (2nd Edition) 2017, 91-123. Elsevier Inc., Amsterdam
Rakic T, Kasagic-Vujanovic I, Jovanovic M, Stojanovic BJ and Ivanovic D (2014). Comparison of full factorial design, central composite design, and Box-Behnken design in chromatographic method development for the determination of fluconazole and its impurities. Anal Lett 47:1334-1347. DOI: 10.1080/00032719. 2013.867503.
Ramisetti NR, and Bompelli S (2014). LC-MS/MS determination of cinacalcet enantiomers in rat plasma on Chirobiotic V column in polar ionic mode: application to a pharmacokinetic study. Biomed Chromatogr 28:1846-1853. DOI: 10.1002/bmc.3229.
Rao RN, Saida S, Naidu CG,Sarvan B, and Ramesh B (2014). Liquid chromatographic separation, determination and ESI-MS/MS, FT-IR and NMR characterization of the forced degradation products of cinacalcet. Anal Methods6: 5076-5087.DOI: 10.1039/C4AY00077C.
Ravinder V, Ashok S, Varma MS, Babu CVR, Shanker K, and Balaswamy G (2009). A validated chiral LC method for the enantiomeric separation of cinacalcet hydrochloride. Chromatographia 70: 229-232.DOI: 10.1365/s10337-009-1129-5.
Sahu PK, Rao RN, Cecchi T, Swain S, Patro CS and Panda J (2018). An overview of experimental designs in HPLC method development and validation. J Pharm Biomed Anal 147: 590- 611.DOI: 10.1016/j.jpba.2017.05.006
Sweetman SC ed. Martindale: The Complete Drug Reference, 36th ed., Pharmaceutical Press, London, 2009, 1095.
Torres PU (2006). Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kindey disease. J Ren Nutr 16: 253-258. DOI: 10.1053/j.jrn.2006.04.010.
Wani TA, Khalil NY, and Darwish I (2014). Highly sensitive and simple validated ultra-performance liquid chromatography/ tandem mass spectrometry method for the determination of cinacalcet in human plasma. Curr Pharm Anal 10: 51-57.
